18 / 18
Page 72
conferenceseries
.com
Volume 2, Issue 4 (Suppl)
Breast Can Curr Res, an open access journal
Breast Pathology 2017
August 23-24, 2017
August 23-24, 2017 Toronto, Canada
4
th
World Congress on
Breast Pathology and Cancer Diagnosis
Breast Can Curr Res 2017, 2:4 (Suppl)
DOI: 10.4172/2572-4118-C1-009
Immunohistochemical analysis of
p53
protein expression in Indian female breast cancer cases:
Correlation with clinico-pathological variables
Mohammad Zeeshan Najm
1
, Syed Akhtar Husain
2
, Sadaf
2
, Md Nasar Mallick
2
and
Meenu Singh
1
1
Noida Institute of Engineering and Technology, India
2
Jamia Millia Islamia Univrsity, India
B
reast cancer has been defined as the most common cancer in women worldwide, with nearly 1.7 million new cases
diagnosed in 2012. We did
p53
protein expression study through immunohistochemistry in 105 cases breast cancer cases
from India. The study was attempted to improve the prognostic and predictive value of
p53
in breast cancer. Prior informed
consent and ethical approval was obtained form Rajiv Gandhi Cancer Hospital and Research Centre, New Delhi, India. All
patients and normal controls were subjected immunohistochemistry using
p53
gene antibody to check the expression level of
p53
protein in paraffin embedded tissue slides of 4mm thickness. All non-neoplastic cases showed no expression for
p53
. In
the tumor samples, immunohistochemical scoring was done as low or no expression (+), moderate expression (++) and high
expression (+++). So, out of 105 cases studied, 26 cases (26/105, 24.80%) had low (+) or no expression of
p53
protein, 50 cases
(50/105, 47.60%) had moderate (++) expression and 29 cases (29/105, 27.60%) had high (+++) expression of
p53
protein. In
our study sample, we were not able to find any significant association between
p53
gene expression and the clinico pathological
variables like age, nodal status, tumor stage, menopausal status, ER status, HER 2 status and histological grade. Our study did
provide the information on the evaluation of
p53
significance in cancer cases from India and larger population based study will
be needed to show the presence or absence of the biomarker property of
p53
in breast cancer.
biotechzeeshan@gmail.com